profil
antibodi
nucleocapsid
protein
sever
acut
respiratori
syndrom
sar
associ
coronaviru
probabl
sar
patient
healthi
peopl
nonsar
patient
analyz
antigencaptur
enzymelink
immunosorb
assay
antinucleocapsid
antibodi
elucid
probabl
sar
patient
day
onset
symptom
patient
day
onset
probabl
sar
patient
posit
day
ill
antibodi
titer
increas
day
high
antibodi
titer
maintain
least
anoth
month
healthi
peopl
nonsar
patient
seven
weakli
posit
fig
develop
antin
protein
antibodi
titer
time
patient
probabl
sar
note
clin
diagn
lab
immunol
march
guest
novel
sever
acut
respiratori
syndrom
sar
associ
coronaviru
cov
identifi
etiolog
agent
sar
demonstr
least
earli
respons
antibodi
nucleocapsid
protein
n
protein
predomin
assay
western
blot
proteom
analysi
understand
humor
immun
n
protein
sar
cov
possibl
use
n
protein
sar
diagnosi
antibodi
n
protein
patient
probabl
sar
diagnos
basi
world
health
organ
criteria
four
hospit
analyz
antigencaptur
enzymelink
immunosorb
assay
recombin
sar
n
protein
use
antigen
method
briefli
describ
follow
nencod
gene
sar
cov
clone
promoterbas
prokaryot
express
vector
novagen
result
recombin
plasmid
pmgn
transform
escherichia
coli
recombin
n
protein
express
e
coli
induct
iptg
sigma
st
loui
mo
mmollit
purifi
ssepharos
fast
flow
ionexchang
chromatographi
follow
gel
filtrat
superdex
amersham
pharmacia
puriti
determin
laser
densitometri
silverstain
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
gel
purifi
n
protein
dilut
gml
mm
carbon
buffer
ph
use
coat
well
micropl
overnight
follow
block
fetal
bovin
serum
h
room
temperatur
addit
n
protein
conjug
horseradish
peroxidas
sigma
antigencaptur
enzymelink
immunosorb
assay
establish
detect
antin
protein
antibodi
present
sera
volum
serum
ad
well
coat
recombin
n
protein
plate
incub
min
wash
five
time
phosphatebuff
salin
contain
tween
volum
label
antigen
ad
plate
incub
anoth
min
wash
alreadi
describ
l
tmb
substrat
solut
mg
tetramethylbenzidin
hydrochlorideml
h
acet
buffer
ph
ad
mixtur
incub
min
reaction
termin
ad
l
n
sulfur
acid
absorb
nm
determin
sampl
averag
standard
deviat
sampl
healthi
peopl
consid
posit
shown
tabl
patient
probabl
sar
develop
antin
protein
antibodi
day
onset
symptom
eighti
percent
patient
posit
day
fall
ill
posit
fall
ill
furthermor
patient
fallen
ill
day
previous
posit
higher
posit
rate
observ
group
could
explain
fact
patient
result
also
indic
assay
valu
sar
diagnosi
day
symptom
onset
antin
protein
antibodi
titer
patient
probabl
sar
determin
serial
dilut
titer
calcul
follow
formula
antibodi
titer
fold
shown
fig
low
antibodi
titer
develop
week
onset
symptom
antibodi
titer
increas
next
week
high
antibodi
titer
maintain
least
anoth
month
decreas
antibodi
titer
observ
day
onset
symptom
serial
sampl
sar
patient
also
assay
profil
similar
report
li
et
al
observ
evalu
specif
assay
antibodi
n
protein
sar
cov
nonsar
patient
health
care
work
healthi
peopl
assay
sampl
shown
weakli
reactiv
cutoff
valu
may
caus
crossreact
antibodi
contamin
trace
amount
e
coli
protein
antigen
use
assay
falseposit
rate
significantli
lower
observ
indirect
enzymelink
immunosorb
assay
use
viru
lysat
antigen
assay
highli
specif
result
indic
assay
antibodi
n
protein
antibodi
sar
cov
could
use
diagnosi
sar
infect
epidemiolog
survey
xl
ys
pl
contribut
equal
work
